In 2023, Hu et al. found that dihydroartemisinin could reduce the expression of an immune checkpoint molecule, B7-H3, in two human NSCLC cell lines, A549 and HCC827, and increase tumor-infiltrating CD8+ T cells in tumor engraftments in a A549 tumor-bearing mouse model [30]. This evidence concerns the gene CD8A and neoplasm.